Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624825 | 1.00 | BACE1 (0.36) | BACE1ALOX5PTPN1APPSIRT2 | |
| SCHEMBL2624826 | 0.94 | ALOX5 (0.38) | BACE1ALOX5PTPN1APPALOX15 | |
| SCHEMBL2624818 | 0.94 | BACE1 (0.36) | BACE1ALOX5PTPN1APPSIRT2 | |
| SCHEMBL2624824 | 0.94 | BACE1 (0.36) | BACE1ALOX5PTPN1APPSIRT2 | |
| SCHEMBL29725717 | 0.91 | BACE1 (0.36) | BACE1ALOX5PTPN1APPSIRT2 | |
| SCHEMBL2624870 | 0.91 | BACE1 (0.36) | BACE1ALOX5PTPN1APPSIRT2 | |
| SCHEMBL2624871 | 0.91 | BACE1 (0.36) | BACE1ALOX5PTPN1APPSIRT2 | |
| SCHEMBL2624817 | 0.89 | BACE1 (0.34) | BACE1ALOX5PTPN1APPMET | |
| SCHEMBL2624835 | 0.89 | BACE1 (0.34) | BACE1ALOX5PTPN1APPMET | |
| SCHEMBL2624866 | 0.89 | PTGS2 (0.38) | BACE1ALOX5PTPN1PTGS2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883462-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883462-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120100579-A1 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-8110596-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20090216028-A1 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216028-A1 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | PLAT, F2R, F12 | BACE1 1351/4885ALOX5 833/4885PTPN1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.